Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831726 · ClinicalTrials.gov registry record · Phase 2
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT01831726 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 80 participants.
The verdict
NCT01831726, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Interventions
- DRUG Dovitinib (TKI258)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01831726
The ClinicalTrials.gov registry entry for NCT01831726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dovitinib (TKI258) is the first listed.
NCT01831726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01831726 about?
NCT01831726 is a clinical study titled "Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib". The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
What is the current status of trial NCT01831726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2013-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01831726?
The interventions under investigation include: Dovitinib (TKI258) (DRUG).
Who is sponsoring clinical trial NCT01831726?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.